AbbVie
ABBV
1,654 hedge funds and large institutions have $70.1B invested in AbbVie in 2016 Q3 according to their latest regulatory filings, with 101 funds opening new positions, 631 increasing their positions, 662 reducing their positions, and 65 closing their positions.
55% more first-time investments, than exits
New positions opened: 101 | Existing positions closed: 65
1% more funds holding
Funds holding: 1,636 → 1,654 (+18)
1.1% more ownership
Funds ownership: 67.18% → 68.28% (+1.1%)
0% more capital invested
Capital invested by funds: $69.8B → $70.1B (+$238M)
5% less repeat investments, than reductions
Existing positions increased: 631 | Existing positions reduced: 662
14% less funds holding in top 10
Funds holding in top 10: 94 → 81 (-13)
15% less call options, than puts
Call options by funds: $636M | Put options by funds: $751M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$554M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$215M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
+$131M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$107M |
| 5 |
State Street
Boston,
Massachusetts
|
+$101M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$768M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$438M |
| 3 |
GCM
Glenview Capital Management
New York
|
-$416M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$216M |
| 5 |
O
OrbiMed
New York
|
-$152M |
ABBV Hedge Fund Activity: Q3 2016 in Review
1,654 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q3 2016, worth a combined $70.1B — up 0.34% from $69.8B a quarter earlier.
Buyers outnumbered sellers: 101 funds opened new ABBV positions and 65 closed out — a net gain of 36 holders — while 631 added to existing stakes and 662 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $554M. The largest seller was Bank of America, cutting an estimated $768M.
- 1,654 institutional investors held AbbVie (ABBV) as of Q3 2016, up from 1,636 in Q2 2016.
- Funds reported $70.1B of AbbVie stock for Q3 2016, up 0.34% quarter-over-quarter.
- 101 funds opened new AbbVie positions in Q3 2016 and 65 closed out, a net change of +36 holders.
- The largest AbbVie buyer in Q3 2016 was Capital Research Global Investors, an estimated $554M added.
- The largest AbbVie seller in Q3 2016 was Bank of America, an estimated $768M sold.
Based on aggregated 13F filings for Q3 2016.